Chemotherapy for colorectal cancer with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside: a pilot study.
Fifty-four patients with clinical evidence of residual colorectal adenocarcinoma following surgical removal of the primary tumor were treated with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside. The objective response rate in these patients was 17%. Bone marrow suppression was the major toxic effect. These data fail to show an advantage of this combination therapy over previously described chemotherapeutic regimens.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008937:Mitomycins / Q000008:administration & dosage; D010865:Pilot Projects; D012004:Rectal Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D008937:Mitomycins; D003561:Cytarabine; D004317:Doxorubicin; D005472:Fluorouracil